Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the market entry of LAMAs (e.g., Boehringer Ingelheim’s Spiriva) and novel biologics (e.g., AstraZeneca’s Fasenra, Sanofi/Regeneron’s Dupixent), an unmet need remains for effective therapies for severe disease, especially for patients whose symptoms are not adequately controlled with current therapies or who depend on frequent SABA or oral corticosteroid use to achieve relief. This Unmet Need report provides quantitative insight into key treatment drivers and goals and the current level of unmet need in severe asthma based on the perceptions of U.S. and European physicians. We analyze the commercial opportunities and how emerging therapies could capitalize on these opportunities.
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of approximately 30 U.S. pulmonologists, 30 U.S. allergists, and 30 European pulmonologists.
Key companies: Roche, Novartis, GlaxoSmithKline, Teva, AstraZeneca, Regeneron, Sanofi, Boehringer Ingelheim.
Key drugs: Xolair, Nucala, Cinqair/Cinqaero, Fasenra, Dupixent, Spiriva (tiotropium).
Already a Client? Log in to access this report.
Shubhendu Ghosh, is a Business Insights Analyst on the Immune and Inflammatory Disorders team at Decision Resources Group, with a primary focus on asthma. Prior to joining DRG, Shubhendu was an Associate Editor at Nature Structural & Molecular Biology and a Copy Editor at Nature Medicine. He was also a Scientific and Developmental Editor at Nature Research Editing Service. Shubhendu received his in Biomedical Sciences from the University of Massachusetts Medical School after completing a B. Sc. in Microbiology from Delhi University and an M. Sc. In Biotechnology from Madurai Kamaraj University.